



WOLFRAM EICHNER, Dr.

Partner & Portfolio Manager Apus Capital

Wolfram Eichner has over 25 years of experience in the pharmaceutical / life science industry working for Beiersdorf AG as well as Fresenius Kabi where he held various executive positions. Wolfram has a broad experience in leading and overseeing drug development programs, most of these initiatives in collaboration with partners in the US, Canada, and Europe. He also has a strong background in dealing with patent/intellectual property matters.

From 2001 to 2005, Wolfram also served as Board member of the Biotech Section of BPI (Federal Association of the Pharmaceutical Industry). In conjunction with a series of educational programs, he transitioned into the Finance Industry back in 2006, where he joined ComInvest Asset Management GmbH (later merged with Allianz Global Investors), working as a financial buy-side analyst for the Healthcare Industry until 2010.

From 2011-2014, Wolfram worked as a principal consultant for Mederi AG while concurrently starting Apus Capital GmbH with other investment professionals. Apus Capital is an investment funds with focus on revaluation cases in various industry segments, primarily IT and Pharma/Biotech.

From 2016-2018 he also served as Member of the Board of Directors of the French MedTech company Theraclion. Wolfram graduated in Biology at the University of Hannover and did his Doctorate at the Society for Biotechnological Research (GBF) in Braunschweig. He holds an MBA from the Technical University of Giessen/Friedberg and is also a Certified Financial Analyst (CEFA).